TickerGraveyard
TickerGraveyard

CYBN

Delisted
CYBIN INC.

CYBN — Post-Mortem

Cybin Inc., a biopharmaceutical company focused on psychedelic therapeutics, experienced a decline in its operational standing, ultimately leading to its delisting from the NYSE American LLC. The company's market activities were severely constrained by compliance challenges, culminating in a Form 25 filing on January 2, 2026, which formally notified the removal of its common shares from the exchange. Despite its pioneering vision in the psychedelic research space, Cybin faced significant challenges that undermined investor confidence and operational viability.

Cybin Inc. was delisted from the NYSE American LLC on January 2, 2026, following a notification of removal from listing due to compliance issues.

Could I Have Seen This Coming?

No structured pre-delisting signals found in our records. Absence of signals does not imply absence of risk.

Post-Mortem Analysis

Five-section narrative grounded in primary filings and contemporaneous reporting.

Origin

Cybin Inc. was founded with a focus on developing psychedelic-based treatments and aimed to reshape the mental health landscape through innovative therapeutic solutions.

Peak

Cybin Inc. had reached a peak operational phase prior to 2025, with significant investor interest fueled by developments in psychedelic therapies for mental health.

Turning Point

The turning point occurred when compliance and operational challenges became evident, raising concerns among investors regarding the financial stability of the company.

End

The end of Cybin's listing on the NYSE American LLC was marked by the submission of Form 25 on January 2, 2026, indicating a voluntary withdrawal due to failure to comply with listing requirements.

Impact

The removal from the exchange signaled a critical loss of market presence, affecting investor sentiment and future potential of the company.

Lessons for Today's Investors

Transferable patterns identified from this case, written as research-report observations.

  1. 1

    Compliance with regulatory requirements is crucial; companies must ensure adherence to exchange rules to avoid delisting.

  2. 2

    A clear communication strategy about a company's operational and financial status is essential to maintain investor trust.

  3. 3

    The financial health of a corporation is closely monitored by various stakeholders, and negative trends can lead to severe repercussions including delisting.

Frequently Asked Questions

Why was Cybin Inc. delisted?
Cybin Inc. was removed from the NYSE American LLC due to compliance issues under the Securities Exchange Act of 1934.
Who filed the Form 25 for Cybin Inc.?
The filing was made by the Chief Financial Officer, Greg Cavers, certifying compliance with the relevant regulations.
Was the delisting voluntary?
The filing indicates that the removal was executed voluntarily by Cybin Inc.
When was the delisting notification filed?
The Form 25 was filed on January 2, 2026.
What is the business of Cybin Inc.?
Cybin Inc. is involved in the biopharmaceutical sector, focusing on psychedelic therapeutics.

Source Filings

Every fact on this page is anchored to a primary SEC filing or regulatory record. Open any source to verify against the original document.

Narrative sections on this page are AI-assisted summaries of the filings linked above. All content is reviewed against primary sources; if you find an error, the canonical record is always the linked filing.

Categories:

Industries:

Tags:

Related tickers:

Share: